<DOC>
	<DOCNO>NCT01523431</DOCNO>
	<brief_summary>The purpose study investigate influence dose selection CPT-11 toxicity , response pharmacokinetics accord UGT1A1 genotype colorectal cancer patient .</brief_summary>
	<brief_title>Individual Dosage Selection Irinotecan ( CPT-11 ) Based UGT1A1 Genotype Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description>Genetic polymorphism UGTs result reduce enzyme activity increase toxicity . UGT1A1*28 UGT1A1*6 report increase CPT-11-related toxicity Asian patient . Moreover , area concentration curve ( AUC ) ratio SN-38G SN-38 decreased Asian patient UGT1A1 *28 UGT1A1*6 . This implicated current standard dose CPT-11 would overdose homozygous UGT1A1*28/*28 , *6/*6 *28/*6 patient . The study design investigate role prospectively dose reduction CPT-11 toxicity , tumor response pharmacokinetics homozygous UGT1A1 patient , compare parameter standard dose CPT-11 wild-type , heterozygous homozygous UGT1A1 patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically confirm colorectal cancer patient receive prior chemotherapy fail 1st line treatment 2 . At least one measurable lesion Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 3 . Aged 18 year old 4 . ECOG performance status ≤ 2 . 5 . Anticipated life expectancy ≥ 3 month . 6 . UGT1A1 genotype test . Categorized Wild ( UGT1A1*1/*1 ) , Hetero ( UGT1A1*1/ *28 , UGT1A1*1/ *6 ) , Homo ( UGT1A1*28/*28 , UGT1A1*6/*6 , UGT1A1*28/*6 ) . 7 . Adequate organ function , include bone marrow , kidney liver . ANC ≥ 1.5×109/L hemoglobin ≥ 9g/dL platelet count ≥ 100×109/L Serum total bilirubin ≤ 1.5 x ULN , alkaline phosphatase ≤ 2.5 x ULN , Serum ALT AST ≤ 2.5 x ULN ( Serum ALT AST ≤ 5 x ULN , liver metastasis present ) Serum creatinine ≤ 1.5 x ULN CLcr &gt; 60 ml/min 8 . Written inform consent obtain prior participation trial . 1 . Pregnant breast feed woman . 2 . Subjects previously receive CPT11 treatment . 3 . Serious concurrent complication , severe active infection . 4 . Subjects chronic diarrhea , acute sub acute Intestinal obstruction . 5 . Subjects uncontrolled CNS metastasis epilepsia severe psychiatric disorder . 6 . Subjects regard unsuitable trial investigator . 7 . Subjects participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>UGT1A1 genotype</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>diarrhea</keyword>
	<keyword>response</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>